Volume 60, Issue 5, Pages (November 2001)

Slides:

Advertisements

Similar presentations

Volume 68, Pages S24-S28 (July 2005)

Advertisements

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Volume 63, Issue 3, Pages (March 2003)

Persistent secondary hyperparathyroidism after renal transplantation

Volume 62, Issue 4, Pages (October 2002)

E. Cavalier, P. Delanaye, A. Carlisi, J. -M. Krzesinski, J. -P

Figure 1. Summary of PTH secretion from human parathyroid cells after caffeine treatment at concentrations of 0, 1, 10, and 50 μm at extracellular calcium.

Volume 60, Issue 6, Pages (December 2001)

Volume 67, Pages S1-S7 (June 2005)

Vitamin D Insufficiency

Renal vitamin D receptor expression and vitamin D renoprotection

Volume 68, Issue 6, Pages (December 2005)

FGF23 or PTH: which comes first in CKD ?

Volume 74, Issue 10, Pages (November 2008)

Vitamin D deficiency and heart disease

Tilman B. Drüeke, Ziad A. Massy Kidney International

RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone Eduardo A. Slatopolsky, Steven K.

Volume 67, Issue 6, Pages (June 2005)

Volume 78, Issue 10, Pages (November 2010)

Volume 62, Issue 4, Pages (October 2002)

FGF23–parathyroid interaction: implications in chronic kidney disease

Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets David M. Spiegel, Kate Brady Kidney.

Volume 79, Pages S24-S27 (April 2011)

Volume 60, Issue 6, Pages (December 2001)

Volume 76, Pages S50-S99 (August 2009)

Volume 80, Issue 8, Pages (October 2011)

Tally Naveh-Many, Justin Silver Kidney International

Graphic Interpretation of Serum Parathyroid Hormone, Calcium, and Phosphorus Values in Primary Hyperparathyroidism Pai C. Kao, Ph.D., Edward G. Lufkin,

Comorbidity and confounding in end-stage renal disease

The new role of calcimimetics as vasculotropic agents

Volume 79, Pages S20-S23 (April 2011)

Magnus Åbrink, Eric Larsson, Anders Gobl, Lars Hellman

Volume 76, Issue 3, Pages (August 2009)

Use of vitamin D in chronic kidney disease patients

Florian Lang, Michael Föller Kidney International

Volume 71, Issue 11, Pages (June 2007)

Volume 79, Issue 1, Pages (January 2011)

Bradley A. Ford, Daniel W. Coyne, Charles S. Eby, Mitchell G. Scott

Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.

Volume 80, Issue 5, Pages (September 2011)

The calcium–phosphorus in guidelines for CKD-MBD

Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism

Volume 55, Issue 1, Pages (January 1999)

Volume 68, Pages S24-S28 (July 2005)

Persistent secondary hyperparathyroidism after renal transplantation

Volume 56, Pages S31-S37 (December 1999)

Volume 87, Issue 3, Pages (March 2015)

Calcium sensing in podocytes

Volume 58, Issue 4, Pages (October 2000)

Volume 75, Issue 9, Pages (May 2009)

Volume 78, Issue 4, Pages (August 2010)

Fibroblast growth factor 23: the making of a hormone

Phosphate and the parathyroid

Volume 73, Issue 5, Pages (March 2008)

Pablo A. Ureña Torres, Marc De Broe Kidney International

Volume 82, Issue 10, Pages (November 2012)

Volume 80, Issue 10, Pages (November 2011)

Increased parathyroid expression of klotho in uremic rats

Volume 65, Issue 3, Pages (March 2004)

Recent developments in the management of secondary hyperparathyroidism

Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease Aquiles Jara, Arnold J. Felsenfeld, Jordi.

Increased fetuin-A levels following treatment with a vitamin D analog

The ins and outs of phosphate homeostasis

Abby S. Kazley, Kit N. Simpson, Kenneth D. Chavin, Prabhakar Baliga

Volume 74, Issue 10, Pages (November 2008)

Volume 55, Issue 4, Pages (April 1999)

Volume 61, Issue 4, Pages (April 2002)

Marta Christov, Harald Jüppner Kidney International

Volume 64, Pages S131-S136 (November 2003)

Regulation of serum calcium homeostasis.

Presentation transcript:

Volume 60, Issue 5, Pages 1666-1675 (November 2001) Heterogeneous expression of receptor mRNAs in parathyroid glands of secondary hyperparathyroidism Stiina Välimäki, M.D., Filip Farnebo, Lars Forsberg, Catharina Larsson, Lars-Ove Farnebo Kidney International Volume 60, Issue 5, Pages 1666-1675 (November 2001) DOI: 10.1046/j.1523-1755.2001.00986.x Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 1 (A) Autoradiogram of consecutive sections of three glands from patient 1 and normal biopsies (upper row only). Frozen sections were hybridized with oligonucleotide probes complementary to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), calcium receptor (CaR), calcium-sensing receptor (CAS), vitamin D receptor (VDR), and parathyroid hormone (PTH) mRNA, and then exposed to x-ray film. Nodular areas are denoted N1 to N6 and internodular areas I1 to I3. A highly variable expression of all mRNAs is shown.(B and C) Autoradiogram of consecutive sections hybridized with probes complementary to GAPDH, CaR, CAS, VDR, and PTH mRNA showing three glands where the expression of VDR mRNA is high and of PTH mRNA low (B) and vice versa (C). In patient 14, a nodule shows high expression of VDR mRNA (B). Kidney International 2001 60, 1666-1675DOI: (10.1046/j.1523-1755.2001.00986.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 1 (A) Autoradiogram of consecutive sections of three glands from patient 1 and normal biopsies (upper row only). Frozen sections were hybridized with oligonucleotide probes complementary to glyceraldehyde-3-phosphate dehydrogenase (GAPDH), calcium receptor (CaR), calcium-sensing receptor (CAS), vitamin D receptor (VDR), and parathyroid hormone (PTH) mRNA, and then exposed to x-ray film. Nodular areas are denoted N1 to N6 and internodular areas I1 to I3. A highly variable expression of all mRNAs is shown.(B and C) Autoradiogram of consecutive sections hybridized with probes complementary to GAPDH, CaR, CAS, VDR, and PTH mRNA showing three glands where the expression of VDR mRNA is high and of PTH mRNA low (B) and vice versa (C). In patient 14, a nodule shows high expression of VDR mRNA (B). Kidney International 2001 60, 1666-1675DOI: (10.1046/j.1523-1755.2001.00986.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 2 Box plot of GAPDH, CaR, VDR and PTH mRNA expression in 36 parathyroid tumors from patients with secondary hyperparathyroidism in relationship to the percent of normal biopsies. The box represents the 25th to the 75th percentile, and the whiskers represent the 10th and the 90th percentiles. The circles represent single values outside the 10th and 90th percentiles. Kidney International 2001 60, 1666-1675DOI: (10.1046/j.1523-1755.2001.00986.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 3 Scattergram showing the correlation between the expression of CaR and CAS mRNA levels. Kidney International 2001 60, 1666-1675DOI: (10.1046/j.1523-1755.2001.00986.x) Copyright © 2001 International Society of Nephrology Terms and Conditions

Figure 4 Vitamin D receptor mRNA expression in nodular parathyroids. A comparison between the nodular (▪) and internodular () areas is shown. Kidney International 2001 60, 1666-1675DOI: (10.1046/j.1523-1755.2001.00986.x) Copyright © 2001 International Society of Nephrology Terms and Conditions